
The fiscal report for Lundbeck's Q3 is something of a mixed bag. Whereas the Danish pharmaceutical company is delivering better results than expected and coming out on the other side of Q3 with decent figures, this picture has more nuances when scrutinized closely.
This is overwhelmingly due to the pandemic, which has boosted figures in some areas, namely operational results, and dampened activities in others.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app